Explore

Trendline Trendline
DaltonTx Launches AI-Powered Drug Discovery Platform with First Client

DaltonTx Launches AI-Powered Drug Discovery Platform with First Client

DaltonTx Launches AI-Powered Drug Discovery Platform with First Client
Trendline Trendline
Chai Discovery and Pfizer Partner to Accelerate Drug Discovery with AI

Chai Discovery and Pfizer Partner to Accelerate Drug Discovery with AI

Chai Discovery and Pfizer Partner to Accelerate Drug Discovery with AI
Trendline Trendline
Regeneron Expands Partnership with CytomX, Potentially Adding $2 Billion and Eight Targets

Regeneron Expands Partnership with CytomX, Potentially Adding $2 Billion and Eight Targets

Regeneron Expands Partnership with CytomX, Potentially Adding $2 Billion and Eight Targets
Trendline Trendline
Chai Discovery and Pfizer Collaborate to Enhance Drug Discovery with AI

Chai Discovery and Pfizer Collaborate to Enhance Drug Discovery with AI

Chai Discovery and Pfizer Collaborate to Enhance Drug Discovery with AI
Trendline Trendline
AstraZeneca CEO Highlights AI's Role in Enhancing Drug Development Success

AstraZeneca CEO Highlights AI's Role in Enhancing Drug Development Success

AstraZeneca CEO Highlights AI's Role in Enhancing Drug Development Success
Trendline Trendline
Regeneron Expands Collaboration with CytomX for Cancer Therapy Development

Regeneron Expands Collaboration with CytomX for Cancer Therapy Development

Regeneron Expands Collaboration with CytomX for Cancer Therapy Development
Trendline Trendline
Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors

Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors

Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors
Trendline Trendline
Incyte and Genesis Expand AI Collaboration to Over $1 Billion for Drug Discovery

Incyte and Genesis Expand AI Collaboration to Over $1 Billion for Drug Discovery

Incyte and Genesis Expand AI Collaboration to Over $1 Billion for Drug Discovery
Trendline Trendline
Eli Lilly Partners with Ascidian Therapeutics for $1.9 Billion RNA Exon Editing Deal Targeting Kidney Diseases

Eli Lilly Partners with Ascidian Therapeutics for $1.9 Billion RNA Exon Editing Deal Targeting Kidney Diseases

Eli Lilly Partners with Ascidian Therapeutics for $1.9 Billion RNA Exon Editing Deal Targeting Kidney Diseases
Trendline Trendline
Eli Lilly Partners with Ascidian for $1.9 Billion Kidney Disease RNA-Editing Collaboration

Eli Lilly Partners with Ascidian for $1.9 Billion Kidney Disease RNA-Editing Collaboration

Eli Lilly Partners with Ascidian for $1.9 Billion Kidney Disease RNA-Editing Collaboration
Trendline Trendline
Corrixr Therapeutics Appoints Hilary M. Malone as CEO to Drive Cancer Treatment Development

Corrixr Therapeutics Appoints Hilary M. Malone as CEO to Drive Cancer Treatment Development

Corrixr Therapeutics Appoints Hilary M. Malone as CEO to Drive Cancer Treatment Development
Reuters Reuters
US FDA to review AI-based tool to predict drug-related liver damage

US FDA to review AI-based tool to predict drug-related liver damage

June 3 (Reuters) - The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of intent for an artificial intelligence-based drug development tool designed to help predict drug-induced liver injury.